Identification

Generic Name
G17DT
DrugBank Accession Number
DB04914
Background

G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Antigastrin 17
  • Gastrin 17 immunogen
  • Gastrin 17 vaccine

Pharmacology

Indication

Intended for the treatment of various forms of cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

G17DT is a vaccine which neutralizes the gastrin 17 (G17) hormone and glycine-extended gastrin 17. G17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid secretion. G17DT consists of a protein carrier (Diptheria Toxoid) and a synthetic peptide which is similar to a portion of the gastrin 17 hormone. These are contained in a 'slow-release' liquid suspension vehicle for intramuscular administration. G17DT is administered by injection, the initial schedule for injection is unclear at present but booster doses are given at approximately six monthly intervals.

Mechanism of action

When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of G17DT can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of G17DT can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of G17DT can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of G17DT can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of G17DT can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of G17DT can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of G17DT can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Gastrimmune / Insegia

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Authors unspecified: Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs. 2003;17(3):223-5. [Article]
  2. Gilliam AD, Watson SA: G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. [Article]
  3. Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1;106(9):1908-16. [Article]
  4. He AR, Marshall JL: Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92. [Article]
  5. Watson SA, Gilliam AD: G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther. 2001 Mar;1(2):309-17. [Article]
  6. Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002 Oct 15;20(20):4225-31. [Article]
  7. Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43. [Article]
  8. Takhar AS, Gilliam AD, Watson SA, Henwood M, Rowlands BJ, Broome P, Beckingham IJ: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol. 2006 Mar;32(2):197-200. Epub 2005 Oct 24. [Article]
PubChem Substance
347909846

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentEsophageal Cancer / Malignant Neoplasm of Stomach1
3CompletedTreatmentMalignant Neoplasm of Pancreas3
2CompletedTreatmentColorectal Cancer4
2CompletedTreatmentJaundice / Malignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Neoplasm of Stomach4
2TerminatedTreatmentColorectal Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52